Exchange: NASDAQ·Updated 07:30 PM EST
MLYS logo

MLYS Mineralys Therapeutics Inc

$13.70
$0.50
(3.53%)
Today
Closed $13.66
$0.04
(0.29%)
After Hours
Reported EarningsNov 4
Mkt Cap$1.21B
Vol1.35M

About MLYS

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
48

Neutral Sentiment

How do you feel about MLYS?

CH_Expat
$MLYS Okay, seems like the exciting high volume selloff period is over. Now we seem to be in the lower than average volume stagnation boring period. So much better.
9
jeffrman777
$MLYS I feel like lack of concrete answers to a lot of the questions can either be read as a really good or really bad sign. They clearly lean towards selling but you can never lean too much on this as an investment thesis.
1
5
dgbio
$MLYS AZN's comments on the launch of Baxfendy: "The way I would describe it's quite an encouraging start. We have already been able to deliver 12,000 new patient starts. As expected, most of those patient starts are in the commercial book of business, because we don't have any coverage yet in Part D, that will take some time. It's not unusual. We have submitted our bids for Part D to all the plans, hopefully we will see the coverage in 2028 coming through. We have bridging programs in place, what is very, let's say, pleasing to see is that both primary care physicians as well as specialists have started to prescribe Baxfendy. Likewise, there's a very healthy split between patients for resistant hypertension as well as for uncontrolled hypertension. So early days, for sure. We are hoping to see more commercial access as we go on in the course of 2028, then full coverage, if possible, in 2027 for commercial and 2028 for Part D".
8
Valueforall
$MLYS when you change your own perspective you welcome this price action if you plan to add more aggressively. Good news validates thesis. Higher conviction. More shares at lower price = amplified gains and ultimate goodness. Patience and fortitude is a must!
1
5
CH_Expat
$MLYS Exhausting, frunstrating, demoralizing. And I am only in here since June. Imagine you bought in 40s. Acceptance is key, they can do what they want, even at 650m EV.
7
roscoe44
$MLYS This one is trending for what just 4 people in this and we talk to each other. Lol
7
CH_Expat
$MLYS Serious question: Did you ever see a more controlled cold blooded dragdown cent by cent? As said: Imminent bad bews sell different. There were six cent spreads all day long.
7
jeffrman777
$MLYS At this point, just give me approval and a clean label, push this to low-20s, then let me offload this thing and be done with it.
2
dgbio
$MLYS Baxfendy sales of $9m dissapoint the market. Two things to keep in mind: • It's the first new hypertension drug in a long while. It takes time to navigate the insurers' bureaucracy. Mineralys will follow on an established path. • Hypertension is a chronic condition, patients are going to be on these drugs for years. This is a long-term recurring revenue.
6
aak12345
$MLYS the current price is insane. If FDA approves the opportunity and need is huge even with Baxfendy in the mix. I think just caught up in small cap/AI selloff
5
AlertsAndNews
$MLYS MLYS Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026 "56% of participants reached AOSBP below 130 mmHg at Week 48 U.S. FDA review of lorundrostat is underway, with a PDUFA target date of December 22, 2026"
5
Bfunk17
$MLYS I will say one thing...I noticed a trend prior to BO with DAWN. The Bid was always parked near the actual price and the Ask was much higher. The spread was always banked north to encourage sellers at the current levels but not necessarily inviting to buyers. This was the case right up until BO. That is the same set-up here...encouraging sellers and making it hard for retail to add. I have no idea if a BO is coming or what kind of run in inbound. But this is a tactic used by MMs and Tutes to grab shares from retail. Again, who TF knows what's next. But it is a trend I have seen prior to good things happening.
5
Valueforall
$MLYS couple observations. Punctured new low this AM. Held back from any xbi rebound connection. Very strange conference call ahead of an important Nov/dec. It’s checking off all those weirdo beardo vibes. Ted lasso ref
1
2
Blind_Trader_
$MLYS bought at 14.9 sold at 15.4, not many shares but little by little my average is coming down
1
1
roscoe44
$MLYS Did anyone find anything useful? Every question is faced with non answer. No answer for partnerships or cost of the drug etc.. repeatedly saying 20 million patients.
4
OnlyBioLover
$MLYS -14% today with no company news. the move came the same day az reported q3: baxfendy did $9M in q3 and $12M ytd. az also said near term revenue comes mostly from commercial plans, with medicare reimbursement expected from 2028. so the whole class is ramping slow. consensus had mlys at ~$79M revenue in 2027, that looks ambitious now. on the other side at ~18 the ev is roughly 1.1b with pdufa on 12/22 and long term data at aha nov 8. not advice.
4
Blind_Trader_
$MLYS I would recommend everyone here to follow a guy on x named biotech2k. he invests in biotech, commercial and pre revenue. but he also invests in bonds and tech... imo a good risk managed portfolio... and most importantly he will give you also insights in his average and strategies. I wouldn't follow him in his trades but is good to see what an experienced guy thinks about the market and how he moves...
3
Bfunk17
$MLYS Just mentioned M&A. 🤔 Spoke about launching and mentioned a possible partner, by themselves or M&A. The M&A is a VERY interesting add there. Companies won't even bring up that topic unless there is something to bring up. So throwing it in there is not an accident. I'd love to know how far along they are in talks with different BPs. Would it be contingent upon FDA approval-type situation? Labeling details? One thing strikes me is that you don't say M&A unless you are interested in M&A. And they don't have a heavy appetitie for a Global launch so we will see how this plays out.
3
Bfunk17
$MLYS Listening to Stifel. I do enjoy that they are drawing a bit more of a comparison vs Bax and asserting that Lorundrostat is just better. He did is subtle today. Also talking about labeling with confidence as if the FDA is already ready to approve the drug. It appears all the FDA conversations have gone quite well because they have a good idea what the label is going to look like.
3
roscoe44
$MLYS Dont touch any stock that i buy. I am the problem and not the stock, i am not even kidding. Everything in my watchlist rebounded except for the stocks i hold not even dead cat bounce. If anyone curious my current holdings are mlys idya and abvx.
3

Advertisement|Remove ads.